What are the recommended treatments for leishmaniasis, including cutaneous, mucocutaneous, and visceral forms?

Treatment of Leishmaniasis

For visceral leishmaniasis, liposomal amphotericin B is the treatment of choice, with single-dose or short-course regimens achieving the highest cure rates; for cutaneous leishmaniasis, topical paromomycin should be used first-line for most lesions, reserving systemic therapy for mucosal risk or severe disease; and for mucosal leishmaniasis, systemic therapy with liposomal amphotericin B or pentavalent antimonials is required to prevent destructive progression 1, 2.

Visceral Leishmaniasis (VL) - Life-Threatening Priority

VL requires immediate systemic treatment as it is potentially fatal if untreated 1.

First-Line Treatment Options by Region:

Indian Subcontinent:

• Single-dose liposomal amphotericin B (L-AmB) is preferred 3
• Alternative: Multidrug combination therapy (L-AmB + miltefosine, L-AmB + paromomycin, or miltefosine + paromomycin) 3
• These regimens reduce treatment duration and improve outcomes compared to traditional antimonials

East Africa:

• 17-day combination of pentavalent antimonials (Sb^v^) + paromomycin remains standard 3
• This reflects regional parasite susceptibility patterns

Mediterranean Region and South America:

• L-AmB at total dose of 18-21 mg/kg 3
• Achieves high cure rates with acceptable toxicity profile

Critical Considerations:

• Liposomal amphotericin B demonstrates the highest cure rates across all VL settings 4
• Miltefosine achieves 94-97% initial cure rates but has 10-20% relapse rates and is teratogenic 5
• All symptomatic VL patients should be considered immunocompromised 1

Cutaneous Leishmaniasis (CL) - Algorithmic Approach

The treatment decision hinges on risk of mucosal progression and lesion characteristics 1, 2.

When to Use Local Therapy:

Topical Paromomycin (Preferred First-Line):

• Use for up to 10 lesions, including those >4 cm 2
• Contraindication: Proximity to mucosal areas (risk of future mucosal disease) 2
• Ease of use makes it broadly applicable for Old World and New World CL without mucosal risk

Cryotherapy ± Intralesional Meglumine Antimoniate:

• Effective for localized Old World CL lesions 2
• Must have no risk of mucosal involvement
• Particularly useful for single, small lesions

When Systemic Therapy is Mandatory:

Absolute Indications for Systemic Treatment 1:

• Infection with Leishmania (Viannia) braziliensis or related species (high mucosal risk)
• Multiple lesions (>10)
• Lesions near or involving mucosal surfaces
• Immunocompromised patients
• Rapidly evolving or extensive disease

Systemic Treatment Options:

1. Pentamidine (IV or IM):

   • Particularly useful for L. guyanensis infections 2
   • Practical for remote settings or multiple lesions

2. Liposomal Amphotericin B:

   • Reserved for treatment failures 2
   • L. infantum in immunosuppressed patients 2
   • Mucosal or rapidly evolving South American lesions 2

3. Miltefosine:

   • Consider when hospitalization impossible 2
   • Major caveat: Teratogenic - requires strict contraception 2

Common Pitfall:

Do not assume all CL requires systemic therapy. The trend toward local treatment for New World CL is appropriate only when mucosal risk is absent 3. Species identification is critical to assess this risk 1.

Mucosal Leishmaniasis (ML) - Aggressive Systemic Approach Required

ML represents metastatic disease, predominantly from L. (V.) braziliensis and related Viannia species, causing destructive naso-oropharyngeal lesions 1.

Treatment Strategy:

Systemic therapy is mandatory 1:

• Liposomal amphotericin B (preferred for efficacy and to prevent progression) 2
• Pentavalent antimonials (alternative, particularly in resource-limited settings) 1

ML can progress to cause severe destruction; suboptimal therapy risks treatment failure and continued tissue damage 1.

Special Populations

HIV/VL Coinfection:

• Requires secondary prophylaxis after initial treatment 6
• Higher relapse rates necessitate long-term management strategies
• All treatment decisions must account for immunosuppression severity

Immunosuppressed Patients:

• L. infantum CL requires liposomal amphotericin B 2
• Higher doses and longer durations often needed
• Close monitoring for relapse essential

Treatment Monitoring

For CL 1:

• Assess response at defined timeframes (typically 4-6 weeks post-treatment)
• Look for re-epithelialization, decreased induration, and lesion flattening
• Non-responders require escalation to alternative systemic agents

For VL:

• Clinical improvement (fever resolution, spleen size reduction) within 1-2 weeks
• Parasitologic cure confirmation when feasible
• Monitor for relapse, especially in HIV-coinfected patients

Key Evidence Considerations

The 2016 IDSA/ASTMH guidelines 1 provide the authoritative framework for North American practice, emphasizing species identification to guide therapy. The 2026 French guidelines 2 offer the most recent algorithmic approach for CL, advocating broader use of topical paromomycin than previously recommended. The evidence consistently shows liposomal amphotericin B as the highest-performing agent for VL across all settings 3, 4, 5, though regional variations in drug availability and parasite susceptibility necessitate geographic tailoring 6, 3.